我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

PCI相关血小板P2Y12受体阻滞剂的研究现况及进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第2期
页码:
236-240
栏目:
综述
出版日期:
2016-11-25

文章信息/Info

Title:
Current status and progress of percutaneous coronary intervention-related platelet P2Y12 receptor blockers
作者:
李 超1; 张英梅1; 李 毅2; 韩雅玲2
（1.第四军医大学西京医院心内科，陕西 西安 710032；
沈阳军区总医院心内科，辽宁 沈阳 110016）
Author(s):
LI Chao1;  ZHANG Ying-mei1;  LI Yi2;  HAN Ya-ling2
(1.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China；
2.Department of Cardiology, Shenyang General Hospital, Shenyang Military Area Command, Shenyang 110016, Liaoning, China)
关键词:
急性冠状动脉综合征; 经皮冠状动脉介入治疗; P2Y12受体阻滞剂
Keywords:
ACS;  PCI;  P2Y12 receptor inhibitors
分类号:
R543.3
DOI:
-
文献标识码:
A
摘要:
抗血小板治疗是心血管领域永恒的话题，全世界学者都努力在出血和血栓之间寻找平衡，对于新型抗血小板药物的研究亦从未停止。目前，阿司匹林与氯吡格雷的双重抗血小板治疗是急性冠状动脉综合征(ACS)患者经皮冠状动脉介入（PCI）治疗围手术期的标准化治疗方案，近年来新型P2Y12受体阻滞剂的出现对这一标准方案提出挑战。本文通过综述各种P2Y12受体阻滞剂抗血小板作用机制及临床特点的异同，为临床上新型P2Y12受体阻滞剂的应用及进一步研究提供理论依据。
Abstract:
Anti-platelet therapy is an ongoing topic in the field of cardiovascular medicine. Worldwide scholars are trying to find a balance between bleeding and thrombosis. The search for new anti-platelet drugs continues. At present, dual anti-platelet therapy of aspirin and clopidogrel is the standard treatment for patients with acute coronary syndrome. In recent years, the emergence of new P2Y12 receptor blockers challenges the standard scheme. In this article, the mechanism and clinical characteristics of anti-platelet effects of various P2Y12 receptor blockers are reviewed, providing a theoretical basis for the clinical application and further research of P2Y12 receptor blockers.

参考文献/References

[1]葛俊波，徐永健.内科学[M].第8版.北京:人民卫生出版社,2014:236-255.
[2]韩雅玲.2013冠心病抗栓治疗进展[J].中国医学信息导报,2013,28(19):16.
[3]姚 懿，袁晋青.新型抗血小板药物普拉格雷、替格瑞洛与氯吡格雷的临床对比研究进展[J].中华临床医师杂志(电子版),2013,7(19):8870-8873.
[4]Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J].Kardiol Pol,2015,73(12):1207-1294.
[5]霍 勇.解读2007年ESC非ST段抬高急性冠脉综合征诊疗指南[J].中国处方药,2007,(10):58-60.
[6]James S,Akerblom A,Cannon CP,et al.Comparison of ticagrelor,the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes:Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J].Am Heart J,2009,157(4):599-605.
[7]关绍义，韩雅玲，李 毅，等.不同剂量西洛他唑强化抗血小板对冠脉支架术后血小板高反应性的影响[J].现代生物医学进展,2013,13(29):5685-5688.
[8]马颖艳，韩雅玲.冠脉介入治疗时期氯吡格雷抵抗的认识与思考——抓住本质,全面获益[J].医学与哲学(临床决策论坛版),2011,32(9):49-50.
[9]韩雅玲，苏庆丰，李 毅，等.冠状动脉介入治疗术后三联抗血小板治疗的近期疗效[J].中华医学杂志,2006,86(16):1093-1096.
[10]李 毅，韩雅玲，杨 勇，等.冠状动脉支架术后三联抗血小板治疗的疗效[J].中国循环杂志,2008,23(2):106-109.
[11]张玉美，韩雅玲，王效增，等.遵循指南药物治疗对急性冠脉综合征患者冠状动脉支架术后近期疗效的影响[J].中国医学工程,2012(06):32-33.
[12]霍 勇，方唯一.卫生部心血管疾病介入诊疗技术培训教材 冠心病分册[M].第2版.北京,卫生部医政司,2013:88-98.
[13]Sabouret P,Taiel-Sartral M.New antiplatelet agents in the treatment of acute coronary syndromes[J].Arch Cardiovasc Dis,2014,107(3):178-187.
[14]Alexopoulos D.p2y12 receptor inhibitors in acute coronary syndromes:from the research laboratory to the clinic and vice versa[J].Cardiology,2014,127(4):211-219.
[15]Menozzi A,Lina D,Conte G,et al.Antiplatelet therapy in acute coronary syndromes[J].Expert Opin Pharmacother,2012,13(1):27-42.
[16]朱建兵，张俊峰.冠心病抗栓药物新进展[J].国际心血管病杂志,2014,41(3):163-166.
[17]Gurbel PA,Erlinge D,Ohman EM,et al.Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization:the TRILOGY ACS platelet function substudy[J]. JAMA,2012,308(17):1785-1794.
[18]Gurbel PA,Bliden KP,Butler K,et al.Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:the RESPOND study[J].Circulation,2010,121(10):1188-1199.
[19]Alexopoulos D,Galati A,Xanthopoulou I,et al.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention:a pharmacodynamic study[J].J Am Coll Cardiol,2012,60(3):193-199.
[20]Mega JL,Close SL,Wiviott SD,et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354-362.
[21]Pare G,Mehta SR,Yusuf S,et al.Effects of CYP2C19 genotype on outcomes of clopidogrel treatment[J].N Engl J Med,2010,363(18):1704-1714.
[22]Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J].Circulation,2009,119(19):2553-2560.
[23]Wallentin L,James S,Storey RF,et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
[24]Harmsze AM,van Werkum JW,Hackeng CM,et al.The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting[J].Pharmacogenet Genomics,2012,22(3):169-175.
[25]Gurbel PA,Bliden KP,Butler K,et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study[J].Circulation,2009,120(25):2577-2585.
[26]Wallentin L,Becker RC,Budaj A,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
[27]Kang HJ,Clare RM,Gao R,et al.Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes(PLATO)Trial[J].Am Heart J,2015,169(6):899-905.
[28]杨晓伟，张君毅，易 甫，等.替格瑞洛对急性冠状动脉综合征择期介入治疗患者近中期疗效观察[J].中华临床医师杂志(电子版),2013,7(19):8696-8700.
[29]Vrijens B,Claeys MJ,Legrand V,et al.Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project)[J].Br J Clin Pharmacol,2014,77(5):746-755.
[30]Wiviott SD,Braunwald E,Mccabe CH,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001-2015.
[31]Montalescot G,Bolognese L,Dudek D,et al.A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study[J].Am Heart J,2011,161(4):650-656.
[32]Biondi-Zoccai G,Lotrionte M,Agostoni P,et al.Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes[J].Int J Cardiol,2011,150(3):325-331.
[33]Pandit A,Aryal MR,Aryal PA,et al.Cangrelor versus clopidogrel in percutaneous coronary intervention: a systematic review and meta-analysis[J].EuroIntervention,2014,9(11):1350-1358.
[34]Bellemain-Appaix A,Brieger D,Beygui F,et al.New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis[J].J Am Coll Cardiol,2010,56(19):1542-1551.
[35]贾媛芳，张雪娟，郭俊杰.血栓弹力图在心血管疾病诊治中的应用进展[J].心血管病学进展,2015,36(2):207-210.
[36]Bonaca MP,Bhatt DL,Braunwald E,et al.Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial[J].Am Heart J,2014,167(4):437-444.

备注/Memo

备注/Memo:
收稿日期：2015-12-12.
通讯作者：韩雅玲，教授，主要从事冠心病的诊断与治疗研究Email：hanyaling@263.net
共同通讯作者：张英梅，副教授，主要从事冠心病的诊断与治疗研究 Email：zhangym197951@126.com
作者简介：李超，主治医师，硕士 Email：lichao19811228@sina.com
更新日期/Last Update: 2016-10-11